The Permission for Clinical Trial for the actives and the tablets of Nifeviroc, a new drug (Class 1.1), was issued on 22nd, March, 2007 by SFDA. Nifeviroc is developed by Shanghai Targetdrug Pharmaceutical Co., Ltd., that is a subsidiary of FDZJ.

Nifeviroc designed and developed the company is classified pharmacologically as a CCR-5 antagonist to inhibit HIV’s activity to entry cells and the project belongs the New Drug 1.1 class. The indication of the drug is anti-AIDS. The pre-clinical study showed that the quality of the drug was easy to control, the preparative technique was reliable, the activities of anti-virus were very strong, the toxicity was lower and characteristic of efficacy and safety. Four patent applications registered in order to bring protection for the IP. One of the patents is for the protection for the new material structure as a PCT.